Fig. 6
From: ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis
Blocking of the ANXA2-related signaling pathway inhibits the growth of ESCC xenograft tumors in vivo. a Western blot analysis of the indicated protein expression in KYSE30 and KYSE150 cells exposed to different concentrations of dasatinib. b-d Nude mice bearing established KYSE150 xenograft tumors were treated with dasatinib, ANXA2 siRNA or bevacizumab either alone or in combination for 3 weeks. The tumor volumes were measured at the indicated time, and the xenograft tumors were resected and weighed after 3 weeks. b Tumor growth curve. c Xenograft tumors. d The weights of xenograft tumors. **, P < 0.01; ***, P < 0.001